98 results
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
25 Apr 24
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
6:46am
Disease and entry into the Innovative Licensing and Access Pathway (ILAP) by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). SAGE … to support our goals; early positive signs from launch or from our engagements with healthcare professionals, patients and payors related to ZURZUVAE
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
17 Apr 24
Regulation FD Disclosure
6:35am
Greene, Chief Executive Officer at Sage Therapeutics. “We are thankful for the patients and healthcare professionals who participated in this research
8-K
EX-99.1
4ito4s
14 Feb 24
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.2
qvn2es3z0b3 mgw
8 Jan 24
Departure of Directors or Certain Officers
6:45am
8-K
fa4lp6gwj tj1uo0n9w
8 Jan 24
Departure of Directors or Certain Officers
6:45am
8-K
EX-1.1
4d6gc
7 Nov 23
Entry into a Material Definitive Agreement
7:39am
424B5
kz6hqy
7 Nov 23
Prospectus supplement for primary offering
7:29am
8-K
EX-99.1
h3k2e rgim1pnhc
7 Nov 23
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
EX-99.1
1m5m1zpd
7 Aug 23
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
ehebl u8zcocgkf38
2 May 23
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
1pmmao9q84is se9ms9
8 Nov 22
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
6:45am